ImmunityBio, Inc. (NASDAQ: IBRX) is a Healthcare company (Biotechnology) with a market capitalization of $6.7B. The Maz Rating grades it against the other companies in its sector.
ImmunityBio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.26, ImmunityBio, Inc. trades at 36.4x sales. Over the last twelve months it generated about $183M of revenue and a net loss of $1.1B. It runs a gross margin of 96.7%, an operating margin of -150.2% and a net margin of -607.8%. It shows return on equity of 124.6%, return on invested capital of -52.9% and a free cash flow yield of -4.5%. On the balance sheet: a debt-to-equity ratio of -0.76 and a current ratio of 4.27. Over the past 52 weeks the share price ranged from $1.95 to $12.43, with a beta of 0.13.
ImmunityBio, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.